Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05450809 · ClinicalTrials.gov registry record
Performance and Accuracy of an AI Enhanced Smart Watch Single Lead ECG
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT05450809: Completed study, sponsored by Mayo Clinic.
NCT05450809 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05450809 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
The purpose of this study is to show the artificial intelligence enhanced single-lead ECG Apple Watch has similar, robust performance comparable to an AI enhanced 12 lead ECG and AI enhanced single lead (LI) of a 12 lead ECG.
Primary Outcome
The ECG interval differences (in milliseconds) between 12 Lead and collected single-lead watch-based ECG for PR, QRS, QT intervals will be determined and compared for each patient.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-11-05 |
| Est. Completion | 2022-11-02 |
What the finished NCT05450809 record still lists
NCT05450809 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05450809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05450809 about?
NCT05450809 is a clinical study titled "Performance and Accuracy of an AI Enhanced Smart Watch Single Lead ECG". The purpose of this study is to show the artificial intelligence enhanced single-lead ECG Apple Watch has similar, robust performance comparable to an AI enhanced 12 lead ECG and AI enhanced single lead (LI) of a 12 lead ECG.
What is the current status of trial NCT05450809?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2021-11-05. Estimated completion is 2022-11-02.
Who is sponsoring clinical trial NCT05450809?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI